Momenta Pharmaceuticals (MNTA) March put volatility elevated at 131
Up)
Momenta Pharmaceuticals (Nasdaq: MNTA) closed at $9.96. The FDA is expected to make a decision on MNTA's M-Enoxaparin (treatment for deep vein thrombosis) in the next nine-months. MNTA November option implied volatility is at 54, January is at 108 and March puts are at 131; verses its six-month average of 98 according to Track Data. Paul Foster
You May Also Be Interested In
- Savient Pharma (SVNT) Moves Higher with Volatility; Bumps Up Against Key Resistance Point
- Cree (CREE) Volatility Elevated as CFO Slide Continues
- Zynga (ZNGA) Holds Above Key Level Amid Increased Volatility; Still Well Below 50-Day SMA
Create E-mail Alert Related Categories
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
